IP Library Assignment 031016/0678
Patent Assignment
Reel/Frame 031016/0678

Merger

Recorded: 2013-08-15 Pages: 4
Assignor
MEDAREX, INC.
Executed: 2012-12-31
Assignee
MEDAREX, L.L.C.
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NEW JERSEY, 08540
Covered Properties (14)
Human Anti-Opgl Neutralizing Antibodies as Selective Opgl Pathway Inhibitors
Patent: 7,718,776 →
Application: 10/408,901 →
Publication: US 2004/0023313
Therapeutic Human Anti-IL1-R1 Monoclonal Antibody
Patent: 7,438,910 →
Application: 10/656,769 →
Publication: US 2004/0097712
Human Anti-Ifn-Gamma Neutralizing Antibodies as Selective Ifn-Gamma Pathway Inhibitors
Patent: 7,335,743 →
Application: 10/684,957 →
Publication: US 2005/0004353
Human Anti-Ngf Neutralizing Antibodies as Selective Ngf Pathway Inhibitors
Patent: 7,601,818 →
Application: 10/891,658 →
Publication: US 2005/0074821
Human Anti-B7RP1 Neutralizing Antibodies
Patent: 7,868,140 →
Application: 11/458,260 →
Publication: US 2008/0166352
Nucleic Acids Encoding Human Anti-Ngf Neutralizing Antibodies as Selective Ngf Pathway Inhibitors
Patent: 7,795,413 →
Application: 11/767,326 →
Publication: US 2008/0033157
Human Anti-Ifn-Gamma Neutralizing Antibodies as Selective Ifn-Gamma Pathway Inhibitors
Patent: 7,790,859 →
Application: 11/962,594 →
Publication: US 2008/0107655
Therapeutic Human Anti-Il-1R1 Monoclonal Antibody
Patent: 8,236,559 →
Application: 12/210,313 →
Publication: US 2009/0214559
Human Anti-Ngf Neutralizing Antibodies as Selective Ngf Pathway Inhibitors
Patent: 8,198,410 →
Application: 12/277,919 →
Publication: US 2009/0155274
Methods of Treating Conditions Caused by Increased Expression of Nerve Growth Factor (Ngf) or Increased Sensitivity to Ngf Using Anti-Ngf Neutralizing Antibodies as Selective Ngf Pathway Inhibitors
Patent: 9,260,514 →
Application: 12/576,522 →
Publication: US 2010/0034818
Nucleic Acid Molecules That Encode Human Anti-Ifn-Gamma Neutralizing Antibodies as Selective Ifn-Gamma Pathway Inhibitors
Patent: 8,202,976 →
Application: 12/831,087 →
Publication: US 2011/0045537
Human Anti-Ngf Neutralizing Antibodies as Selective Ngf Pathway Inhibitors
Patent: 8,106,167 →
Application: 12/859,246 →
Publication: US 2011/0040076
Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
Application: 12/880,961 →
Publication: US 2011/0091476
Methods for Treating Ifn-Gamma Mediated Diseases Using Human Anti-Ifn-Gamma Neutralizing Antibodies as Selective Ifn-Gamma Pathway Inhibitors
Patent: 8,529,893 →
Application: 13/476,317 →
Publication: US 2012/0269819
Related Assignments (6)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest May 17, 2012
From: WELCHER, ANDREW A.; CHUTE, HILARY T.; LI, LUKE; HUANG, HAICHUN
To: AMGEN INC.
Reel/Frame 028229/0279 →
Assignment of Assignor's Interest May 17, 2012
From: AMGEN INC.
To: MEDAREX, INC.
Reel/Frame 028229/0337 →
Merger May 22, 2015
From: MEDAREX, L.L.C.
To: E. R. SQUIBB & SONS, L.L.C.
Reel/Frame 035695/0204 →
Merger May 29, 2015
From: MEDAREX, L.L.C.
To: E. R. SQUIBB & SONS, L.L.C.
Reel/Frame 035741/0438 →
Merger Jun 2, 2015
From: MEDAREX, L.L.C.
To: E. R. SQUIBB & SONS, L.L.C.
Reel/Frame 035767/0494 →
Merger Jun 2, 2015
From: MEDAREX, L.L.C.
To: E. R. SQUIBB & SONS, L.L.C.
Reel/Frame 035767/0746 →